“These interim trial results show that hydroxychloroquine and lopinavir/ritonavir produce little or no reduction in the mortality of hospitalized Covid-19 patients when compared to standard of care. Solidarity trial investigators will interrupt the trials with immediate effect,” the WHO said in a statement, referring to large multicountry trials that the agency is leading. Another branch of the WHO-led trial is looking at the potential effect of Gilead’s antiviral drug remdesivir on Covid-19. The solidarity trial started out with five branches looking at possible treatment approaches to Covid-19: standard care; remdesivir; hydroxychloroquine; lopinavir/ritonavir; and lopanivir/ritonavir combined with interferon. Some 18 experimental Covid-19 vaccines are being tested on humans among nearly 150 treatments under development.

Source: Dhaka Tribune July 04, 2020 18:33 UTC